Quadrature Capital Ltd Buys Shares of 13,251 Baxter International Inc (NYSE:BAX)

Share on StockTwits

Quadrature Capital Ltd purchased a new position in shares of Baxter International Inc (NYSE:BAX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 13,251 shares of the medical instruments supplier’s stock, valued at approximately $1,141,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BAX. Lincoln National Corp lifted its position in shares of Baxter International by 4.4% during the 1st quarter. Lincoln National Corp now owns 7,582 shares of the medical instruments supplier’s stock worth $615,000 after purchasing an additional 323 shares during the last quarter. Public Employees Retirement Association of Colorado raised its holdings in Baxter International by 3.8% in the 1st quarter. Public Employees Retirement Association of Colorado now owns 92,130 shares of the medical instruments supplier’s stock valued at $7,480,000 after acquiring an additional 3,401 shares in the last quarter. Harwood Advisory Group LLC acquired a new position in Baxter International in the 1st quarter valued at approximately $32,000. SG Americas Securities LLC raised its holdings in Baxter International by 17.0% in the 1st quarter. SG Americas Securities LLC now owns 31,496 shares of the medical instruments supplier’s stock valued at $2,557,000 after acquiring an additional 4,580 shares in the last quarter. Finally, Natixis Advisors L.P. raised its holdings in Baxter International by 16.1% in the 1st quarter. Natixis Advisors L.P. now owns 67,738 shares of the medical instruments supplier’s stock valued at $5,500,000 after acquiring an additional 9,385 shares in the last quarter. Institutional investors own 84.23% of the company’s stock.

In other Baxter International news, Director John D. Forsyth sold 1,500 shares of Baxter International stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $82.95, for a total value of $124,425.00. Following the sale, the director now owns 35,398 shares of the company’s stock, valued at approximately $2,936,264.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Giuseppe Accogli sold 72,341 shares of Baxter International stock in a transaction dated Friday, June 19th. The shares were sold at an average price of $85.00, for a total value of $6,148,985.00. Following the completion of the sale, the senior vice president now directly owns 76,473 shares in the company, valued at approximately $6,500,205. The disclosure for this sale can be found here. Insiders have sold a total of 88,740 shares of company stock worth $7,560,833 in the last ninety days. 0.13% of the stock is currently owned by company insiders.

Several equities analysts have commented on BAX shares. Argus cut Baxter International from a “buy” rating to a “hold” rating in a report on Friday. Raymond James cut their price target on Baxter International from $97.00 to $95.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Morgan Stanley cut their price target on Baxter International from $95.00 to $90.00 and set an “equal weight” rating for the company in a report on Friday, July 31st. Oppenheimer reaffirmed a “buy” rating on shares of Baxter International in a report on Thursday, July 30th. Finally, Credit Suisse Group reissued a “buy” rating and issued a $99.00 target price on shares of Baxter International in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $96.72.

NYSE BAX traded down $1.17 during trading hours on Friday, reaching $82.30. 3,143,819 shares of the company’s stock were exchanged, compared to its average volume of 3,144,006. The stock has a market cap of $41.66 billion, a PE ratio of 24.86, a price-to-earnings-growth ratio of 2.77 and a beta of 0.79. Baxter International Inc has a one year low of $69.10 and a one year high of $95.19. The company has a current ratio of 2.97, a quick ratio of 2.31 and a debt-to-equity ratio of 0.74. The firm has a fifty day moving average of $85.22 and a 200-day moving average of $85.80.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $0.64 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.71 by ($0.07). The business had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.86 billion. Baxter International had a return on equity of 20.75% and a net margin of 8.10%. The business’s quarterly revenue was down 4.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.89 EPS. As a group, research analysts forecast that Baxter International Inc will post 3.05 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Monday, August 31st will be paid a dividend of $0.245 per share. This represents a $0.98 annualized dividend and a yield of 1.19%. The ex-dividend date of this dividend is Friday, August 28th. Baxter International’s payout ratio is presently 29.61%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Further Reading: Why is the LIBOR significant?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply